During the last session, Sagimet Biosciences Inc (NASDAQ:SGMT)’s traded shares were 0.34 million, with the beta value of the company hitting 2.39. At the end of the trading day, the stock’s price was $3.68, reflecting an intraday gain of 0.82% or $0.03. The 52-week high for the SGMT share is $7.41, that puts it down -101.36 from that peak though still a striking 35.05% gain since the share price plummeted to a 52-week low of $2.39. The company’s market capitalization is $112.88M, and the average trade volume was 974.57K shares over the past three months.
Sagimet Biosciences Inc (SGMT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.25. SGMT has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.63.
Sagimet Biosciences Inc (NASDAQ:SGMT) trade information
Sagimet Biosciences Inc (SGMT) registered a 0.82% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.82% in intraday trading to $3.68, hitting a weekly high. The stock’s 5-day price performance is -0.94%, and it has moved by -28.27% in 30 days. Based on these gigs, the overall price performance for the year is -39.17%.
The consensus price target of analysts on Wall Street is $6, which implies an increase of 38.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $6 respectively. As a result, SGMT is trading at a discount of -63.04% off the target high and -63.04% off the low.
Sagimet Biosciences Inc (SGMT) estimates and forecasts
In the rating firms’ projections, revenue will decrease -100.00% compared to the previous financial year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -16.23%. While earnings are projected to return 42.25% in 2025, the next five years will return -21.33% per annum.
SGMT Dividends
Sagimet Biosciences Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Also, the Mutual Funds coming in first place with the largest holdings of Sagimet Biosciences Inc (SGMT) shares are Vanguard Total Stock Market Index Fund and BlackRock Health Sciences Term Trust . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 763.99 shares. This amounts to just over 2.49 percent of the company’s overall shares, with a $2.81 million market value. The same data shows that the other fund manager holds slightly less at 408.12, or about 1.33% of the stock, which is worth about $1.5 million.
